Corient Private Wealth
NVAX icon

Corient Private Wealth’s Novavax NVAX Stock Holding History

Corient Private Wealth’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
+16,412
New +$147K ﹤0.01% 2865

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Corient Private Wealth's NVAX Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Novavax (NVAX) in Q2 2026: 16,412 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #2865 among its holdings.

267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Corient Private Wealth held 16,412 shares of Novavax worth $155K as of Q2 2026.
  • Novavax was a new Corient Private Wealth position in Q2 2026.
  • Novavax made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2865 holding.
  • 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.